Maxcyte Inc

MXCT
295,00
0,00 (0,00%)
26 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: Londra
Tipo: Azione Ordinaria
Valuta: GBX

Ultime notizie

Data Ora Fonte Titolo
10/4/202414:05GLOBEMaxCyte to Report First Quarter 2024 Financial Results on..
10/4/202414:05LSEG_RNSMaxCyte, Inc. Notice of Results
03/4/202408:00LSEG_RNSMaxCyte, Inc. Total Voting Rights and Block Listing Return
02/4/202416:19ALNCNewsTRADING UPDATES: MaxCyte inks deal with Be Bio; Orcadian..
02/4/202414:05LSEG_RNSMaxCyte, Inc. Signing of Strategic Platform License
02/4/202414:05GLOBEMaxCyte Signs Strategic Platform License with Be Biopharma..
02/4/202408:00LSEG_RNSMaxCyte, Inc. Exercise of options and PDMR dealing
20/3/202411:16LSEG_RNSMaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR..
20/3/202411:05LSEG_RNSMaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR..
13/3/202412:54ALNCNewsIN BRIEF: MaxCyte loss widens in 2023 as core revenue..
13/3/202408:05LSEG_RNSMaxCyte, Inc. Filing of form 10-K for FY ended December 31,..
13/3/202408:00LSEG_RNSMaxCyte, Inc. Reports Q4 & FY 2023 Financial Results
12/3/202421:05UKREGMaxCyte Reports Fourth Quarter and Full Year 2023 Financial..
06/3/202409:58LSEG_RNSMaxCyte, Inc. TR-1: Notification of major holdings
05/3/202421:43ALNCNewsEARNINGS: dotdigital eyes rosy future; Beeks Financial turns..
05/3/202408:00LSEG_RNSMaxCyte, Inc. Preliminary FY Results & 2024 Guidance
04/3/202422:05UKREGMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023..
01/3/202418:57LSEG_RNSMaxCyte, Inc. Total Voting Rights
29/2/202410:21LSEG_RNSMaxCyte, Inc. Exercise of options and PDMR dealing
26/2/202408:00LSEG_RNSMaxCyte, Inc. TR-1: Notification of major holdings
09/2/202414:05LSEG_RNSMaxCyte, Inc. Notice of Results
09/2/202414:05UKREGMaxCyte to Report Fourth Quarter and Full Year 2023..
01/2/202410:24LSEG_RNSMaxCyte, Inc. Total Voting Rights
31/1/202408:00LSEG_RNSMaxCyte, Inc. Director/PDMR Shareholding
30/1/202415:29LSEG_RNSMaxCyte, Inc. Holding(s) in Company
30/1/202414:58ALNCNewsIN BRIEF: MaxCyte signs licencing deal with cell therapy..
30/1/202414:05LSEG_RNSMaxCyte, Inc. Signing of Strategic Platform License
30/1/202414:05UKREGMaxCyte and Wugen Sign Strategic Platform License to..
29/1/202418:56ALNCNewsIN BRIEF: MaxCyte chief scientific officer leaves firm
29/1/202417:52LSEG_RNSMaxCyte, Inc. TR-1: Notification of major holdings
29/1/202408:00LSEG_RNSMaxCyte, Inc. Filing of Form 8-K
23/1/202419:39ALNCNewsTRADING UPDATES: Esken's Southend Airport faces further..
23/1/202414:05UKREGMaxCyte, Inc. Signing of Strategic Platform License
23/1/202414:05GLOBEMaxCyte Signs Strategic Platform License with Imugene to..
09/1/202413:18ALNCNewsMaxCyte's strategic platform licences redeem otherwise..
09/1/202408:00UKREGMaxCyte, Inc. Preliminary Unaudited Q4 and FY 2023 Results
08/1/202422:05GLOBEMaxCyte Announces Preliminary Unaudited Fourth Quarter and..
05/1/202408:00UKREGMaxCyte, Inc. Grant of Options and PDMR Dealing
03/1/202415:04ALNCNewsMaxCyte teams with Singapore-based Lion to support TCR-T..
03/1/202414:05GLOBEMaxCyte and Lion TCR form Partnership to Support Global..
03/1/202414:05UKREGMaxCyte, Inc. Signing of Strategic Platform License
02/1/202410:23UKREGMaxCyte, Inc. Total Voting Rights
02/1/202408:00GLOBEMaxCyte Confirms Appointment of Maher Masoud as President,..
02/1/202408:00UKREGMaxCyte, Inc. Confirmation of Board change
29/12/202308:00UKREGMaxCyte, Inc. Exercise of options and PDMR dealing
12/12/202316:56ALNCNewsTRADING UPDATES: Technology Minerals identifies lithium at..
12/12/202308:00UKREGMaxCyte, Inc. CEO Transition and Revenue Guidance Update
11/12/202322:05GLOBEMaxCyte Announces CEO Transition and Updates Revenue..
07/12/202310:50UKREGMaxCyte, Inc. Exercise of options and PDMR dealing
04/12/202308:00UKREGMaxCyte, Inc. Exercise of options and PDMR dealing
Apertura: 295,00 Min: 295,00 Max: 295,00
Chiusura: 295,00

La tua Cronologia

Delayed Upgrade Clock

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network